Vitalea Science and Accium BioSciences Announce Initiation of Two-Way Cooperative Agreement to Cross-Validate Accelerator Mass Spectrometer (AMS) Resources

Share Article

Vitalea Science and Accium BioSciences, leading providers of bioanalytical contract services based on Accelerator Mass Spectrometry (AMS), have entered a cooperative agreement to provide expanded capacity and redundancy to address continued demand from US and International clients.

Vitalea Science and Accium BioSciences, leading providers of bioanalytical contract services based on Accelerator Mass Spectrometry (AMS), are pleased to announce the initiation of a cooperative agreement and launch of a series of internal studies to cross-validate each other’s AMS platform. Successful completion of these studies will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework. Pharmaceutical companies may continue to request the services of either Vitalea or Accium with the added reassurance of backup measurement capacity, instrument redundancy and highest quality standards.

AMS is an ultrasensitive detection platform that often complements other tools available to the bioanalytical scientist. Notably, AMS provides proven solutions for quantifying the pharmacokinetics and metabolism of drug candidates in humans, both prior to and as part of Phase 1 clinical trials. AMS also offers specific advantages in preclinical models and in the development of biologic-based therapeutics.

“Capacity and the ability to consistently meet our Sponsor’s timelines are key factors in securing and maintaining business,” commented Bob Bethem, Chief Executive Officer at Vitalea. “Accium and Vitalea will continue to compete for AMS studies worldwide but our labs share a common guiding principle to shape our AMS services according to industry expectations. We will continue to provide the highest level of study design and execution at Vitalea with the added reassurance of this new backup contingency plan.”

“We are excited to embark on these cross-validation studies and offer expanded capacity and redundancy to new and existing clients,” said Ali Arjomand, President and Chief Operating Officer at Accium. “Vitalea's co-founder, Stephen Dueker, and I have a scientific relationship that dates back to the pioneering days of biomedical AMS research at the University of California and Lawrence Livermore National Laboratory in the mid-1990s. The cooperative agreement announced here will bridge the AMS resources and technical expertise of both companies and provide greater value to pharmaceutical sponsors and the AMS community at large.”

Previously, the two companies independently performed bioanalytical procedures and AMS measurement of samples generated in a sponsored study. The results demonstrated “acceptable accuracy & precision of the AMS measurements at both labs via the use of QC samples. Dog plasma samples measured by the two AMS labs were comparable to each other and were similar to values obtained by LC-MS/MS.” Vitalea and Accium are excited to build on that success by completing cross-validation studies that will expand instrument capacity and redundancy at both facilities.

To learn more about AMS services provided by Vitalea ( or Accium ( and this cooperative agreement, please contact Ann Hoffman (ahoffman(at)vitaleascience(dot)com) Vitalea Science at (530) 341-0200 or Accium BioSciences (info(at)acciumbio(dot)com) at (206) 281-3915 ext. 301.

About Vitalea
Vitalea Science is a GLP compliant facility and is the first U.S.-based bioanalytical contract research organization dedicated to providing services for exploring the pharmacokinetics and metabolism of drug candidates directly in humans. Headquartered in Davis, California, Vitalea offers the BioMICADAS AMS platform, the only AMS instrument purpose-built, in collaboration with the Swiss Federal Institute of Technology, to address the specific needs of the pharmaceutical industry.

About Accium
Accium BioSciences is a provider of GLP-compliant accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Based in Seattle, Washington, Accium operates a National Electrostatics Model 1.5SDH-1 Pelletron Accelerator, a dual acceleration (tandem) electrostatic accelerator. Accium’s customers use AMS to obtain critical information in pharmacokinetics, metabolism, absolute bioavailability and mass balance.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ann Hoffman

Ali Arjomand
Visit website